

Looks Can Be Deceiving: A Case of Non-Lupus Full House Membranous Nephropathy

Beatriz Gil de Oliveira Braga^{1*}, Ana Cristina dos Santos Cunha¹, Gonçalo Emanuel da Silva Medeiros Araújo Carrola², José Ramón Vizcaino^{2,3}, Josefina Maria Sousa Santos Lascasas^{1,3}

1. Nephrology Department, Unidade Local de Saúde de Santo António, Porto, Portugal;

2. Pathology Department, Unidade Local de Saúde de Santo António, Porto, Portugal;

3. UMIB- Unit for Multidisciplinary Research in Biomedicine, Porto, Portugal

<https://doi.org/10.71749/pkj.76>

Keywords: Glomerulonephritis, Membranous

A 69-year-old woman with diabetes, hypertension, and dyslipidemia presented with five months of peripheral edema and foamy urine. Laboratory tests showed declining renal function (creatinine 2.18 mg/dL) and nephrotic-range proteinuria (9 g/g). Autoimmune and infectious serologies were negative, anti-PLA2R antibodies were elevated (375 U/mL), and cancer screening was unremarkable.

Kidney biopsy revealed thickened glomerular basement membranes with a spike-like pattern (Fig. 1 A-C). Immunofluorescence demonstrated a full-house pattern with granular deposits of IgG, IgA, IgM, C3, and C4 (Fig. 2: A-E). Immunohistochemistry confirmed PLA2R and IgG4 positivity (Fig. 2- F-G).

Since the kidney biopsy findings supported a diagnosis of primary membranous nephropathy (MN) despite the atypical immunofluorescence pattern, she was treated

with rituximab due to its high risk.¹ Six months later, renal function stabilized (creatinine 2.3 mg/dL), proteinuria decreased (UPCR 2.5 g/g), and anti-PLA2R antibody levels dropped to 4.5 U/mL. Given the full-house pattern, continued follow-up was recommended to monitor for evolving lupus features or other secondary processes.

This case illustrates the complexity of MN with an unusual immune profile.² The coexistence of anti-PLA2R antibodies and a full-house immunofluorescence pattern suggests an intersection of different immune-mediated mechanisms.³ The occurrence of full-house glomerular deposits in the absence of a clinical diagnosis of systemic lupus erythematosus could indicate a more pronounced defect in immune complex clearance stemming from abnormal immune regulation.⁴ Further research is needed to clarify the implications of such overlapping features and to guide the best therapeutic strategies for similar cases.

Received: 08/02/2025 **Accepted:** 24/03/2025 **Published Online:** 27/03/2025 **Published:-**

* **Corresponding Author:** Beatriz Gil de Oliveira Braga | beatrizgilbraga.nefrologia@chporto.min-saude.pt | Largo do Professor Abel Salazar, 4050-366, Porto Portugal

© Author(s) (or their employer(s)) and PKJ 2025. Re-use permitted under CC BY 4.0. (<https://creativecommons.org/licenses/by/4.0/>)




Figure 1. A and B: Kidney biopsy in Hematoxylin and eosin stain. (A: 200 x magnification- B- 400 x magnification): Tubular atrophy and glomeruli showing diffuse and prominent thickening of the glomerular basement membrane.; C- Jones methenamine silver demonstrating a hair-on-end pattern of subepithelial "spikes" (arrows) of the glomerular basement membrane.




Figure 2. The immunofluorescence study (Immunofluorescence (400x magnification)) in kidney biopsy revealed peripheral granular deposits for, IgG (3+) (A), IgM (2+) (B), IgA (2+) (C), and C3 (1+) (D), C4 (1+) (E). Immunohistochemistry in kidney biopsy study showed reactivity for IgG4 (F) and PLA2R (G) in a peripheral granular pattern.

Awards and Previous Presentation

Presented as poster in Encontro Renal de 2022.

Ethical Disclosures

Conflicts of Interest: The authors have no conflicts of interest to declare.

Financing Support: This work has not received any contribution, grant or scholarship.

Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication of patient data.

Patient Consent: Consent for publication was obtained.

Contributorship Statement

BGB: Draft of the article.

AC and JSL: Critical review.

GC and JRV: Analysis and image processing.

All authors approved the final version to be published.

REFERENCES

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. *Kidney Int.* 2021;100:S1-S276. doi: 10.1016/j.kint.2021.05.021.
2. Ye J, Croom N, Troxell ML, Kambham N, Zuckerman JE, Andeen N, et al. Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset. *Kidney360.* 2023;4:935-42. doi: 10.34067/KID.000000000000161.
3. Lusco MA, Fogo AB, Najafian B, Alpers CE. *AJKD Atlas of Renal Pathology: Membranous Lupus Nephritis, ISN/RPS Class V.* *Am J Kidney Dis.* 2017;70:e13-e15. doi: 10.1053/j.ajkd.2017.06.003.
3. Dias CB, Barbosa LJ, Testagrossa L, Malhareiros DA, Woronik V. Clinicopathological study of Non-Lupus Full-House nephropathy. *J Nephrol Ther.* 2018;8:2 doi: 10.4172/2161-0959.1000306.